A Phase I Trial of Tamibarotene and Arsenic Trioxide for the Treatment of Relapsed Acute Promyelocytic Leukemia
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Acute Promyelocytic Leukemia
Both
Acute Promyelocytic Leukemia
Trial Information
A Phase I Trial of Tamibarotene and Arsenic Trioxide for the Treatment of Relapsed Acute Promyelocytic Leukemia
Inclusion Criteria:
- Must have diagnosis of relapsed APL
- Must have completed any prior cancer treatment at least 6 months prior to study
- Must have had prior treatment that included ATRA
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To determine the safety and feasibility of combining tamibarotene and arsenic (ATO) for the treatment of patients with relapsed APL.
Outcome Time Frame:
Once the MTD has been reached.
Safety Issue:
Yes
Authority:
United States: Food and Drug Administration
Study ID:
NU 08H9
NCT ID:
NCT00985530
Start Date:
October 2009
Completion Date:
May 2011
Related Keywords:
- Acute Promyelocytic Leukemia
- Leukemia
- Leukemia, Promyelocytic, Acute
Name | Location |
|---|---|
| Northwestern University | Chicago, Illinois 60611 |
